Silo Pharma Inc. Common Stock (SILO)

FairStock Score: 55/100 — STEADY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable advantages, sound finances, and a margin of safety. Silo Pharma does not fit that mold. It is a three-employee development-stage biotech with no meaningful commercial revenue. In fiscal year 2025, the year ended 2025-12-31, revenue was $72,102 and net loss was $4.2M. In fiscal year 2024, the year ended 2024-12-31, revenue was $72,102 and net loss was $4.4M. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $18,026 and net loss was $1.6M, a margin of -9,137.45%. In fiscal Q2 2026, the quarter ended 2026-06-30, net loss was $832,829 and diluted EPS was -$0.76. The company burns cash: trailing free cash flow is -$3.9M, a FairStock-calculated FCF yield of -56.2% at the 2026-10-13 close. FairStock also calculates P/E of -0.29, ROE of -91.23%, ROCE of -44.25%, Piotroski score of 2/9, and Altman Z-score of -1.19, all pointing to financial weakness. The one valuation curiosity is P/B of 0.28, meaning the $7.0M market cap is below stated book value. But book value in a cash-burning biotech can erode, and the 52-week range of $0.22 to $7.95 shows how speculative the shares can be. Revenue growth is 0.00%, and the Lynch category is none because losses have persisted in each of the last four years. SPC-15 for PTSD is optionality, not a moat. Without profits, cash flow, or a proven product, the margin of safety is theoretical.

In plain English: Silo Pharma is a very small biotech with three employees working on treatments for PTSD, anxiety, fibromyalgia, and brain-related conditions. It has almost no revenue, loses millions of dollars a year, and burns cash. The stock price looks cheap compared with the company's accounting value, but the business itself looks weak and highly risky.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer